All In Biotech

Drug Trial Radar · NCT00375830

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Last checked: Nov 20, 2026Latest source record: Dec 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

114

Actual

Start

Jan 2006

Primary completion

Apr 17, 2017

Study completion Mar 14, 2019

Sponsor

Lead sponsor
Stanford UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 13, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.

Conditions

  • Cancer

Interventions

  • Bone scanProcedure

    Scan to diagnose a number of bone conditions including cancer or metastasis

  • 99mTc-methyl diphosphonateDrug

    Radiolabel for bone scan procedures

  • Positron Emission Tomography (PET) scanProcedure

    Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F

  • 18F-Fludeoxyglucose (18F-FDG)Drug

    Radiolabel for positron emission tomography scan procedures

  • Computed Tomography (CT) scanProcedure

    Scan to detect \& analyze X-rays

  • 18F-Sodium Fluoride (18F-NaF)Drug

    Radiolabel for CT and PET scans, \& as a contrast agent for MRI scans.

  • Whole Body Magnetic Resonance Imaging (WB-MRI) scanProcedure

    Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields \& radio waves to generate images of the organs in the body.

  • Gadopentetate dimeglumineDrug

    A gadolinium-based contrast agent for MRI

  • GadofosvesetDrug

    A gadolinium-based contrast agent for MRI

  • GadobutrolDrug

    A gadolinium-based contrast agent for MRI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1 - NaF PET/CT vs 99mTc-MDP Bone ScintigraphyTime frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stanford University School of Medicine

    Stanford, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.